Breaking News

Velesco Pharma Awarded Subcontract for Blood Disorder Drug

The development, manufacturing, and testing of the drug will help to treat Beta-Thalassemia

Velesco Pharmaceutical Services, Inc. has been awarded a $350,000 subcontract for the development, manufacturing, and testing of the stability of an investigational drug. The drug is intended to treat Beta-Thalassemia, a blood disorder that reduces the production of proteins that carry oxygen to cells throughout the body.   The subcontract is fully funded by the National Center for Advancing Translational Sciences (NCATS) through its Therapeutics for Rare and Neglected Diseases (TRND) pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters